Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Vistide marketing collaboration established

Aug. 23, 1996

WHO studies role of progesterone in HIV transmission

Aug. 16, 1996

HIV vaccine research at NIAID

Aug. 16, 1996

HIV integrase inhibitor effective, non-toxic in vitro

Aug. 16, 1996

Higher doses of GEM-91 administered in phase I/II trial

Aug. 16, 1996

Preclinical development of GEM-92 underway at Hybridon

Aug. 16, 1996

Bayer discloses HIV protease inhibitors

Aug. 16, 1996

VX-478 covered under U.S. patent for HIV/AIDS

Aug. 9, 1996

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

Aug. 9, 1996

GalaGen's Sporidin G enters phase II/III

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...